HRP20240157T1 - Deuterirani derivati lanifibranora - Google Patents
Deuterirani derivati lanifibranora Download PDFInfo
- Publication number
- HRP20240157T1 HRP20240157T1 HRP20240157TT HRP20240157T HRP20240157T1 HR P20240157 T1 HRP20240157 T1 HR P20240157T1 HR P20240157T T HRP20240157T T HR P20240157TT HR P20240157 T HRP20240157 T HR P20240157T HR P20240157 T1 HRP20240157 T1 HR P20240157T1
- Authority
- HR
- Croatia
- Prior art keywords
- derivative according
- deuterated derivative
- groups
- pharmaceutically acceptable
- deuterated
- Prior art date
Links
- OQDQIFQRNZIEEJ-UHFFFAOYSA-N 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid Chemical class C1=C2N=CSC2=CC(S(=O)(=O)N2C3=CC=C(Cl)C=C3C=C2CCCC(=O)O)=C1 OQDQIFQRNZIEEJ-UHFFFAOYSA-N 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- OQDQIFQRNZIEEJ-NMFSSPJFSA-N 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]-2,2,3,3,4,4-hexadeuteriobutanoic acid Chemical group S1C=NC2=C1C=C(C=C2)S(=O)(=O)N1C(=CC2=CC(=CC=C12)Cl)C(C(C(C(=O)O)([2H])[2H])([2H])[2H])([2H])[2H] OQDQIFQRNZIEEJ-NMFSSPJFSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 125000004431 deuterium atom Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000003086 pulmonary systemic sclerosis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Claims (10)
1. Deuterirani derivat lanifibranora formule (I):
[image]
,
naznačen time što je najmanje jedna od skupina R1 do R7 atom deuterija, a druge skupine R1 do R7 su atomi vodika, te njegove farmaceutski prihvatljive soli i solvati.
2. Deuterirani derivat u skladu s patentnim zahtjevom 1, naznačen time što je u najmanju ruku skupina R1 D.
3. Deuterirani derivat u skladu s patentnim zahtjevom 2, naznačen time što je 4-(1-(2-deuterio-1,3-benzotiazol-6-il)sulfonil)-5-klor-1H-indol-2- il)butanska kiselina.
4. Deuterirani derivat u skladu s patentnim zahtjevom 1, naznačen time što je najmanje jedna od skupina R2 do R7 D.
5. Deuterirani derivat u skladu s patentnim zahtjevom 4, naznačen time što je najmanje jedna od skupina R2 i R3 i/ili najmanje jedna od skupina R4 i R5 i/ili najmanje jedna od skupina R6 i R7 D.
6. Deuterirani derivat u skladu s patentnim zahtjevom 5, naznačen time što je 4-[1-(1,3-benzotiazol-6-ilsulfonil)-5-klorindol-2-il]-2,2,3,3,4,4-heksadeuteriobutanska kiselina.
7. Pripravak, naznačen time što sadrži deuterirani derivat u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili jednu od njegovih soli ili solvata, kao i pogodan nosač.
8. Farmaceutski pripravak, naznačen time što sadrži deuterirani derivat u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegovu farmaceutski prihvatljivu sol ili solvat, kao i farmaceutski prihvatljivi nosač.
9. Deuterirani derivat u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što je namijenjen upotrebi u terapiji.
10. Deuterirani derivat u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time što je namijenjen upotrebi u liječenje fibrotičnih bolesti, koje se osobito bira između: fibroze jetre, steatoze jetre, nealkoholnog steatohepatitisa, kronične bolesti bubrega, fibrotičnog plućnog poremećaja, poput idiopatske plućne fibroze, te sistemne skleroze.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1857021A FR3084254B1 (fr) | 2018-07-27 | 2018-07-27 | Derives deuteres du lanifibranor |
| PCT/FR2019/051860 WO2020021215A1 (fr) | 2018-07-27 | 2019-07-26 | Derives deuteres du lanifibranor |
| EP19759658.8A EP3830085B1 (fr) | 2018-07-27 | 2019-07-26 | Derives deuteres du lanifibranor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240157T1 true HRP20240157T1 (hr) | 2024-04-12 |
Family
ID=63684156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240157TT HRP20240157T1 (hr) | 2018-07-27 | 2019-07-26 | Deuterirani derivati lanifibranora |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210300913A1 (hr) |
| EP (2) | EP3830085B1 (hr) |
| JP (2) | JP7434278B2 (hr) |
| CN (1) | CN112638911A (hr) |
| DK (1) | DK3830085T3 (hr) |
| FI (1) | FI3830085T3 (hr) |
| FR (1) | FR3084254B1 (hr) |
| HR (1) | HRP20240157T1 (hr) |
| HU (1) | HUE065045T2 (hr) |
| LT (1) | LT3830085T (hr) |
| PL (1) | PL3830085T3 (hr) |
| PT (1) | PT3830085T (hr) |
| RS (1) | RS65095B1 (hr) |
| SI (1) | SI3830085T1 (hr) |
| WO (1) | WO2020021215A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102199640B1 (ko) * | 2020-01-06 | 2021-01-07 | 브렉소젠 주식회사 | 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물 |
| EP4000616A1 (en) * | 2020-11-17 | 2022-05-25 | Inventiva | Combination therapy for the treatment of a liver disease |
| CN116829144A (zh) * | 2020-12-29 | 2023-09-29 | 广东东阳光药业股份有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| IL310703A (en) * | 2021-08-12 | 2024-04-01 | Crystal Pharmaceutical Suzhou Co Ltd | A crystalline form of lenifibrenor, a method for its preparation and use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| BR112016029129A2 (pt) | 2014-06-13 | 2018-01-30 | Inventiva | compostos ppar para serem utilizados no tratamento de doenças fibróticas. |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| WO2018039521A1 (en) | 2016-08-26 | 2018-03-01 | Concert Pharmaceuticals, Inc. | Deuterated cenicriviroc |
| US11504380B2 (en) * | 2019-11-08 | 2022-11-22 | Inventiva | Method of treatment of cirrhosis |
-
2018
- 2018-07-27 FR FR1857021A patent/FR3084254B1/fr active Active
-
2019
- 2019-07-26 EP EP19759658.8A patent/EP3830085B1/fr active Active
- 2019-07-26 WO PCT/FR2019/051860 patent/WO2020021215A1/fr active Application Filing
- 2019-07-26 US US17/261,938 patent/US20210300913A1/en active Pending
- 2019-07-26 RS RS20240090A patent/RS65095B1/sr unknown
- 2019-07-26 JP JP2021504431A patent/JP7434278B2/ja active Active
- 2019-07-26 SI SI201930700T patent/SI3830085T1/sl unknown
- 2019-07-26 LT LTEPPCT/FR2019/051860T patent/LT3830085T/lt unknown
- 2019-07-26 HU HUE19759658A patent/HUE065045T2/hu unknown
- 2019-07-26 PL PL19759658.8T patent/PL3830085T3/pl unknown
- 2019-07-26 HR HRP20240157TT patent/HRP20240157T1/hr unknown
- 2019-07-26 EP EP23201458.9A patent/EP4331584A1/fr active Pending
- 2019-07-26 CN CN201980049453.4A patent/CN112638911A/zh active Pending
- 2019-07-26 PT PT197596588T patent/PT3830085T/pt unknown
- 2019-07-26 FI FIEP19759658.8T patent/FI3830085T3/fi active
- 2019-07-26 DK DK19759658.8T patent/DK3830085T3/da active
-
2024
- 2024-02-07 JP JP2024017170A patent/JP2024036611A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7434278B2 (ja) | 2024-02-20 |
| EP3830085A1 (fr) | 2021-06-09 |
| JP2024036611A (ja) | 2024-03-15 |
| FI3830085T3 (fi) | 2024-01-17 |
| DK3830085T3 (da) | 2024-01-22 |
| EP3830085B1 (fr) | 2023-11-08 |
| PT3830085T (pt) | 2024-01-24 |
| JP2021533101A (ja) | 2021-12-02 |
| CN112638911A (zh) | 2021-04-09 |
| FR3084254A1 (fr) | 2020-01-31 |
| WO2020021215A1 (fr) | 2020-01-30 |
| PL3830085T3 (pl) | 2024-04-15 |
| HUE065045T2 (hu) | 2024-04-28 |
| RS65095B1 (sr) | 2024-02-29 |
| FR3084254B1 (fr) | 2020-10-23 |
| EP4331584A1 (fr) | 2024-03-06 |
| SI3830085T1 (sl) | 2024-03-29 |
| LT3830085T (lt) | 2024-02-12 |
| US20210300913A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| HRP20210957T1 (hr) | Spojevi inhibitori autotaksina | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2014037426A5 (hr) | ||
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| JP2017528503A5 (hr) | ||
| HRP20120830T1 (hr) | Imidazolkarboksamidi | |
| HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
| JP2013510825A5 (hr) | ||
| US20230012615A1 (en) | Methods for treatment of fibrotic diseases | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| HRP20231608T1 (hr) | Derivati piridinil sulfonamida, njihovi farmaceutski pripravci i njihove uporabe | |
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| RU2017134551A (ru) | Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств | |
| JP2017528506A5 (hr) | ||
| JP2012523440A5 (hr) | ||
| ME01564B (me) | Adicione soli amina koji sadrže hidroksilne i/ ili karboksilne grupe s derivatima aminonikotinske kiseline kao dhodh inhibitorima | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2005508368A5 (hr) | ||
| MX2010001082A (es) | Composicion farmaceutica que contiene compuesto opticamente activo que tiene actividad agonista del receptor de trombopoyetina y compuesto intermedio para el mismo. | |
| JP2009040767A5 (hr) | ||
| HRP20181027T1 (hr) | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a | |
| JP2014525427A5 (hr) | ||
| HRP20120257T1 (hr) | Antagonisti receptora 5-ht7 |